摘要
μ目的比较左西孟旦和多巴酚丁胺治疗扩张型心肌病的临床效果。方法选择2016年11月-2019年6月南通市第六人民医院收治的扩张型心肌病患者128例,依据随机数字表法将128例患者分为观察组(n=64)与对照组(n=64)。对照组在常规治疗的基础上静脉泵入盐酸多巴酚丁胺注射液,5μg/(kg·min),持续24 h。观察组在常规治疗的基础上给予左西孟旦注射液,初始负荷剂量:6~12μg/kg,静注,时间>10 min,然后静脉泵入0.05~0.2μg/(kg·min),持续24 h。7 d为1个疗程,两组治疗共1疗程。观察两组患者的临床疗效,同时比较两组治疗前后的心功能指标、心肌力学指标和血清学指标。结果治疗后,观察组总有效率高于对照组(P<0.05)。治疗后,两组左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)均降低,左室射血分数(LVEF)均明显升高(P<0.05),且观察组LVESV、LVEDV均低于对照组,LVEF均高于对照组(P<0.05)。治疗后,两组长轴应变值(GLS)、径向应变值(GRS)、面积应变值(GAS)均明显增加(P<0.05),且观察组GLS、GRS、GAS均高于对照组(P<0.05)。治疗后,两组半乳凝集素3 (Gal-3)、β2微球蛋白(β2-MG)、可溶性ST2(sST2)水平均明显降低(P<0.05),且观察组Gal-3、β2-MG、sST2均低于对照组(P<0.05)。结论左西孟旦治疗扩张型心肌病可显著改善患者心功能,提高心肌收缩能力,抑制分泌Gal-3、β2-MG、sST2,提高疗效,安全可靠,值得推荐于扩张型心肌病患者的临床治疗。
Objective To compare the clinical efficacy of levosimendan and dobutamine in treatment of dilated cardiomyopathy.Methods Patients(128 cases) with dilated cardiomyopathy in the Sixth People’s Hospital of Nantong from November 2016 to June2019 were divided in to observation group(64 cases) and control group(64 cases) according to random number table method.Patients in the control group was intravenously injected with Dobutamine Hydrochloride Injection at 5 μg/(kg·min) for 24 h on the basis of conventional treatment. On the basis of conventional treatment, patients in the observation group was given Levosimendan Injection with an initial loading dose of 6 - 12 μg/kg, the infusion time was longer than 10 min, followed by intravenous pumping0.05 - 0.2 μg/(kg·min) for 24 h. 7 days as a course of treatment, two groups were treated for 1 course. The clinical effects of two groups were observed, and the indexes of cardiac function, myocardial mechanics, and serology before and after treatment were compared.Results After treatment, the total effective rate of the observation group was higher than that of the control group(P <0.05). After treatment, LVESV and LVEDV in two groups were significantly decreased, but the LVEF were increased(P < 0.05).And LVESV and LVEDV in the observation group were significantly lower than those in the control group, LVEF were higher than those in the control group(P < 0.05). After treatment, GLS, GRS, and GAS in two groups were significantly increased(P < 0.05).And GLS, GRS, and GAS in the observation group were significantly higher than those in the control group(P < 0.05). After treatment, Gal-3, β2-MG, and sST2 in two groups were significantly decreased(P < 0.05). And the levels of Gal-3, β2-MG, and sST2 in the observation group were significantly lower than those in the control group(P < 0.05). Conclusion Levosimendan in treatment of dilated cardiomyopathy can significantly improve the cardiac function and myocardial contractility, inhibit the secretion of Gal-3, β2-MG, sST2, and
作者
周晓兰
刘建云
ZHOU Xiaolan;LIU Jianyun(Department of Cardiology,the Sixth People's Hospital of Nantong,Nantong 226011,China)
出处
《药物评价研究》
CAS
2020年第4期755-759,共5页
Drug Evaluation Research
